![]() |
These embryonic stem cells were generated from embryos left over from people undergoing IVF. Image: Prue Talbot at the University of California, Riverside |
Without this measure, people in New Mexico undergoing IVF had three options for their left over embryos: store them indefinitely, donate them to another woman attempting pregnancy through IVF or destroy them. When researchers have surveyed people going through IVF, they’ve found that a large number would prefer donating embryos to research over these other options.
States in the U.S. have a patchwork of laws, allowing people in some states to donate left over embyos to research but prohibiting that option in other states. If this measure passes the house and is signed by the governor, couples in New Mexico will have the option of research donation when they have completed their family.
We’ve blogged in the past about embryo donation:
People who undergo IVF are often left with excess embryos after they complete their families or abandon the process. Storing these embryos in nitrogen comes with a monthly or yearly cost, which is why many people choose to stop storing, which destroys the embryo, donate to another couple or donate to science. In some cases, donating to science includes donating the embryo for stem cell research.We also have information on our website about how new cell lines are generated from IVF embryos.
A.A.
Brainstorm Cell Therapeutics Inc : Rasheda Ali on National and Local News: BrainStorm’s ALS Clinical Trial Results Exceeded Expectations
ReplyDeleteRasheda Ali on Breakthroughs in Stem Cell Research
Rasheda sits down with Erika to chat about recent stem cell developments and its impact on Parkinsons and ALS.
http://www.nbcnewyork.com/on-air/as-seen-on/Rasheda-Ali-on-breakthroughs-in-stem-cell-research_New-York.html
February 27, 2013
Rasheda Ali on National and Local News: BrainStorm's ALS Clinical Trial Results Exceeded Expectations
NEW YORK & PETACH TIKVAH, Israel-February 27, 2013-- BrainStorm Cell Therapeutics (OTC.QB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced that the company was recently featured on national and local news, as well as Fox News.
Rasheda Ali, a member of BrainStorm's advisory board and revered author and daughter of renowned boxer Muhammad Ali, discussed BrainStorm's promising ALS clinical trials last week on NBC NY and Current TV's Viewpoint. She was also interviewed on Fox News' Geraldo at Large and Neil Cavuto shows.
In her various interviews, Ms. Ali stated that BrainStorm's Phase I/II ALS clinical trial results with its NurOwn™ stem cell candidate exceeded scientists' expectations, surpassing the goal of confirming safety by also showing initial signs of clinical improvement. She also discussed BrainStorm's recent acceleration to a Phase IIa trial by the Israeli Ministry of Health.
Ms. Ali's interviews can be viewed at the following links:
NBC NY: http://bit.ly/Xam0rG.
Current TV Viewpoint: http://bit.ly/13VDZRY